Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21
names for tirzepatide Zepbound vs Compounded Side-by-Side Comparison Size:Single new-year-2026-aus Influencer with Stomach Paralysis
Influencer with Stomach Paralysis Addresses GLP-1 Speculation (Exclusive)
Blood pressure reductions of 5-10 mmHg are common, often allowing patients to reduce or discontinue hypertension medications
new-year-2026-aus
Size:Single
25 mg/day oral Tirzepatide 15 mg/week Retatrutide 12 mg/week Liraglutide 3.0 mg/day Factor Peak trial weight loss Semaglutide -14.9% at 68 wks (STEP 1) Tirzepatide -22.5% at 72 wks (SURMOUNT-1) Retatrutide -28.7% at 68 wks (TRIUMPH-4) Liraglutide -8% at 56 wks (SCALE) Factor FDA status (June 2026) Semaglutide Approved (T2D, obesity, CVD, MASH, CKD, oral) Tirzepatide Approved (T2D, obesity) Retatrutide Investigational - Phase 3 Liraglutide Approved (Saxenda obesity, Victoza T2D) Factor CV outcomes data Semaglutide Yes - SELECT (20% MACE drop) Tirzepatide SURPASS-CVOT ongoing Retatrutide TRIUMPH-3 ongoing Liraglutide Yes - LEADER (13% MACE drop) These compounds are not interchangeable
US$ 23.37
US$ 22.81
US$ 29.09
US$ 21.66
US$ 20.01
US$ 28.15
US$ 27.22
US$ 26.42
US$ 22.97
